Ozempic drug maker reports success with diabetes drug 

German dialysis provider Fresenius Medical Care's shares plunged as much as 24% in Frankfurt trade on news of the study's results

Stopping the Ozempic trial early points to a “somewhat faster effect than we had previously contemplated”.

Novo Nordisk said its diabetes drug Ozempic showed surprisingly early effectiveness in a kidney-failure study, sending shares of the world’s biggest dialysis providers tumbling.

An independent data monitoring committee recommended halting the study after finding that an interim analysis had already met pre-set criteria for efficacy, Novo said. The Danish drug maker will get full results of the study once the process of closing it is complete, expected by the first half of 2024.